 Bioavailability iron hemodialysis patients erythropoietin evidence inhibitory role aluminum dose recombinant human erythropoietin r-HuEPO anemia end-stage renal disease ESRD varies patients response r-HuEPO impaired absolute relative iron deficiency exists Aluminum microcytic anemia patients ESRD mechanism Twenty-two patients Canadian Multicentre EPO trial months randomized double-blind placebo-controlled trial free erythrocyte protoporphyrin FEP indicator iron-deficient deficient erythropoiesis relationship FEP estimates iron availability serum iron transferrin saturation ferritin utilization reticulocyte count hemoglobin multiple linear regression analysis effect aluminum FEP statistical model variable patients iron replete serum ferritin FEP aluminum administration r-HuEPO aluminum treated group hemodialysis patients r-HuEPO proportion variability parameters iron utilization iron availability effect aluminum hemodialysis patients r-HuEPO proportion variability FEP model aluminum data support hypothesis interferes bioavailability stored iron erythropoiesis microcytic anemia patients ESRD response r-HuEPO therapy